Yolanda Bryce

Memorial Sloan Kettering Cancer Center

Papers

1

Total Citations

2

H-Index

1

About

Dr. Yolanda Bryce is a pioneering oncologist whose research bridges immunotherapy, cryoablation, and breast cancer treatment, with a particular focus on triple-negative breast cancer (TNBC)—one of the most aggressive subtypes. Her landmark work, a randomized phase II study published in 2019, investigates the peri-operative combination of ipilimumab, nivolumab, and cryoablation versus standard care in women with residual, early-stage, resectable TNBC after neoadjuvant chemotherapy. This study, which has garnered 2 citations, represents a novel approach to harnessing the immune system through localized tumor destruction, aiming to improve outcomes in a patient population with high recurrence risk. Dr. Bryce’s contributions are notable for integrating interventional oncology techniques with cutting-edge immunotherapy, potentially transforming treatment paradigms for hard-to-treat cancers. Her work underscores a commitment to personalized, multimodal strategies that address unmet needs in breast cancer care. For students and researchers, Dr. Bryce exemplifies how cross-disciplinary innovation can drive progress in oncology, offering hope for more effective, less toxic therapies.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
2 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: Memorial Sloan Kettering Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago